We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




LAMP Assay Validated for MRSA in Invasive Samples

By LabMedica International staff writers
Posted on 16 Jun 2017
Staphylococcus aureus is a leading cause of bone and joint infections and one of the most common causative pathogens of bacterial pneumonia in children. More...
An increased risk of mortality from invasive staphylococcal infections has been attributed to methicillin-resistant S. aureus (MRSA).

The detection of pathogens by loop-mediated isothermal amplification (LAMP), which is a rapid, cost-effective, and simple method with high sensitivity, has resolved the major limitations of time-consuming culture-based methods and costly polymerase chain reaction (PCR) molecular techniques.

Molecular microbiologists at the University Hospital of Sant Joan de Déu (Barcelona, Spain) evaluated the analytical and diagnostic performance of the eazyplex MRSA test system for the detection of S. aureus and MRSA in invasive samples such as pleural and synovial fluid, in comparison to the gold standard bacterial culture. A volume of spiked pleural sample (analytical validation) or pleural/synovial fluid (diagnostic validation) was diluted in sterile water and genomic DNA was extracted using the NucliSENS EasyMag system.

The team pipetted 25 mL of a DNA mixture were into the six wells of the eazyplex MRSA strip. This contains a reagent mix and six primers in each cap for the simultaneous but individual amplification of Staphylococcus epidermidis- and S. aureus-specific genes, as well as resistance genes mecA and mecC for the detection of MRSA. Amplification products were generated by isothermal autocycling DNA synthesis and visualized by real-time fluorescence measurement with the Genie II device.

The new system appropriately detected a quality control panel of clinical samples with DNA of methicillin-sensitive S. aureus (MSSA), MRSA, and other pathogens. The limit of detection (LoD) was established at 6.4 × 103 CFU/mL for S. aureus and 1.0 × 104 CFU/mL for MRSA. Diagnostic validation of the eazyplex MRSA assay was performed on 51 prospective clinical invasive samples, resulting in sensitivity and specificity values of 83.3% and 97.8%, respectively, for S. aureus detection. The mean turnaround time was 70 minutes.

The authors concluded that the eazyplex MRSA test system was found to have promising potential as a diagnostic tool for the early detection of S. aureus in samples collected from normally sterile body sites. The study was published on in the June 2017 issue of the International Journal of Infectious Diseases.

Related Links:
University Hospital of Sant Joan de Déu


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.